<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: substantially dependent upon", fill: "#6f4e37"},
{source: "6: substantially dependent upon", target: "6: contribution", fill: "#6f4e37"},
{source: "6: contribution", target: "6: acquisition expectations since", fill: "#6f4e37"},
{source: "6: acquisition expectations since", target: "6: adversely affected", fill: "#6f4e37"},
{source: "6: substantially dependent upon", target: "9: December ", fill: "#e6be8a"},
{source: "9: December ", target: "10: focus on maximizing sales", fill: "#3d2b1f"},
{source: "10: focus on maximizing sales", target: "10: existing products", fill: "#3d2b1f"},
{source: "10: existing products", target: "10: particularly", fill: "#3d2b1f"},
{source: "10: particularly", target: "10: prescriptions", fill: "#3d2b1f"},
{source: "10: focus on maximizing sales", target: "14: Competitors ", fill: "#fdd5b1"},
{source: "14: Competitors ", target: "14: could offer", fill: "#fdd5b1"},
{source: "14: could offer", target: "14: product competitive with", fill: "#fdd5b1"},
{source: "14: Competitors ", target: "18: products expires competitors could", fill: "#e08d3c"},
{source: "18: products expires competitors could", target: "18: introduce competitive products which may reduce", fill: "#e08d3c"},
{source: "18: introduce competitive products which may reduce", target: "18: such products", fill: "#e08d3c"},
{source: "18: products expires competitors could", target: "22: successfully integrate", fill: "#fbec5d"},
{source: "22: successfully integrate", target: "22: existing operations", fill: "#fbec5d"},
{source: "22: successfully integrate", target: "23: certain rights", fill: "#8a795d"},
{source: "23: certain rights", target: "23: drug products", fill: "#8a795d"},
{source: "23: drug products", target: "23: manufacture", fill: "#8a795d"},
{source: "23: certain rights", target: "29: integration", fill: "#ffe135"},
{source: "29: integration", target: "29: operations", fill: "#ffe135"},
{source: "29: operations", target: "29: unsuccessful", fill: "#ffe135"},
{source: "29: unsuccessful", target: "29: delayed then", fill: "#ffe135"},
{source: "29: delayed then", target: "29: return from", fill: "#ffe135"},
{source: "29: integration", target: "32: existing product lines", fill: "#8b8589"},
{source: "32: existing product lines", target: "32: existing products by offering", fill: "#8b8589"},
{source: "32: existing products by offering", target: "32: alternatives through", fill: "#8b8589"},
{source: "32: alternatives through", target: "32: acquisition", fill: "#8b8589"},
{source: "32: acquisition", target: "32: certain rights", fill: "#8b8589"},
{source: "32: certain rights", target: "32: products there", fill: "#8b8589"},
{source: "32: existing product lines", target: "35: supply us with", fill: "#89cff0"},
{source: "35: supply us with", target: "35: sufficient quantity", fill: "#89cff0"},
{source: "35: sufficient quantity", target: "35: products provided will meet", fill: "#89cff0"},
{source: "35: products provided will meet", target: "35: specifications", fill: "#89cff0"},
{source: "35: supply us with", target: "39: investigating", fill: "#e6be8a"},
{source: "39: investigating", target: "39: manufacturer", fill: "#e6be8a"},
{source: "39: manufacturer", target: "39: manufacturing", fill: "#e6be8a"},
{source: "39: investigating", target: "51: revenues by increasing sales", fill: "#ffefd5"},
{source: "51: revenues by increasing sales", target: "51: actively promoted products", fill: "#ffefd5"},
{source: "51: actively promoted products", target: "51: new products", fill: "#ffefd5"},
{source: "51: revenues by increasing sales", target: "88: contractual rights", fill: "#ace1af"},
{source: "88: contractual rights", target: "88: remedies which", fill: "#ace1af"},
{source: "88: remedies which", target: "88: manufacturers", fill: "#ace1af"},
{source: "88: manufacturers", target: "88: no control over", fill: "#ace1af"},
{source: "88: no control over", target: "88: availability", fill: "#ace1af"},
{source: "88: contractual rights", target: "START_HERE", fill: "#ace1af"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diversification_(marketing_strategy)">Diversification (marketing strategy)</a></td>
      <td>Diversification is a corporate strategy to enter into a new products or product lines, new services or new markets, involving substantially different skills, technology and knowledge.\nDiversification is one of the four main growth strategies defined by Igor Ansoff in the Ansoff Matrix:\nAnsoff pointed out that a diversification strategy stands apart from the other three strategies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_innovation">Product innovation</a></td>
      <td>Product innovation is the creation and subsequent introduction of a good or service that is either new, or an improved version of previous goods or services. This is broader than the normally accepted definition of innovation that includes the invention of new products which, in this context, are still considered innovative.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_strategy">Product strategy</a></td>
      <td>Product strategy defines the high-level plan for developing and marketing a product, how the product supports the business strategy and goals, and is brought to life through product roadmaps. A product strategy describes a vision of the future with this product, the ideal customer profile and market to serve, go-to-market and positioning (marketing), thematic areas of investment, and measures of success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_Apple_Inc._products">Timeline of Apple Inc. products</a></td>
      <td>This timeline of Apple Inc. products is a list of all stand-alone Apple II, Macintosh, and other computers, as well as computer peripherals, expansion cards, ancillary products, and consumer electronics sold by Apple Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_acquisition">Language acquisition</a></td>
      <td>Language acquisition is the process by which humans acquire the capacity to perceive and comprehend language (in other words, gain the ability to be aware of language and to understand it), as well as to produce and use words and sentences to communicate.\nLanguage acquisition involves structures, rules and representation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knowledge_acquisition">Knowledge acquisition</a></td>
      <td>Knowledge acquisition is the process used to define the rules and ontologies required for a knowledge-based system. The phrase was first used in conjunction with expert systems to describe the initial tasks associated with developing an expert system, namely finding and interviewing domain experts and capturing their knowledge via rules, objects, and frame-based ontologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phase-gate_process">Phase-gate process</a></td>
      <td>A phase-gate process (also referred to as a stage-gate process or waterfall process) is a project management technique in which an initiative or project (e.g., new product development, software development, process improvement, business change) is divided into distinct stages or phases, separated by decision points (known as gates).\nAt each gate, continuation is decided by (typically) a manager, steering committee, or governance board.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerospace_manufacturer">Aerospace manufacturer</a></td>
      <td>An aerospace manufacturer is a company or individual involved in the various aspects of designing, building, testing, selling, and maintaining aircraft, aircraft parts, missiles, rockets, or spacecraft. Aerospace is a high technology industry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Original_equipment_manufacturer">Original equipment manufacturer</a></td>
      <td>An original equipment manufacturer (OEM) is generally perceived as a company that produces parts and equipment that may be marketed by another manufacturer.\nHowever, the term is also used in several other ways, which causes ambiguity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_price">List price</a></td>
      <td>The list price, also known as the manufacturer's suggested retail price (MSRP), or the recommended retail price (RRP), or the suggested retail price (SRP) of a product is the price at which its manufacturer notionally recommends that a retailer sell the product.\nSuggested pricing methods may conflict with competition theory, as they allow prices to be set higher than would be established by supply and demand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_modern_armament_manufacturers">List of modern armament manufacturers</a></td>
      <td>The following list of modern armament manufacturers presents major companies producing modern weapons and munitions for military, paramilitary, government agency and civilian use. The companies are listed by their full name followed by the short form, or common acronym, if any, in parentheses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_design">Product design</a></td>
      <td>Product design as a verb is to create a new product to be sold by a business to its customers. A very broad coefficient and effective generation and development of ideas through a process that leads to new products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_aircraft_manufacturers">List of aircraft manufacturers</a></td>
      <td>This is a list of aircraft manufacturers sorted alphabetically by International Civil Aviation Organization (ICAO)/common name. It contains the ICAO/common name, manufacturers name(s), country and other data, with the known years of operation in parentheses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_loudspeaker_manufacturers">List of loudspeaker manufacturers</a></td>
      <td>This is a list of notable manufacturers of loudspeakers. In regard to notability, this is not intended to be an all-inclusive list; it is a list of manufacturers especially noted for their loudspeakers and which have articles on Wikipedia.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>FIRST HORIZON PHARMACEUTICAL CORP      ITEM 1A        RISK FACTORS       An <font color="blue">investment</font> in our <font color="blue"><font color="blue">common stock</font> involves</font> a high degree of risk</td>
    </tr>
    <tr>
      <td>You should     <font color="blue">carefully</font> consider the <font color="blue">following risk factors</font> and all other information     contained in this <font color="blue">Annual Report</font></td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties described</font> below     are not the only ones we are <font color="blue">facing risks</font> and <font color="blue">uncertainties may become</font>     <font color="blue">important factors</font> that <font color="blue">affect us</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       If any of the <font color="blue">following risks</font> occur, our business, <font color="blue">financial condition</font> or     results of <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In that     case, the <font color="blue">trading price</font> of our <font color="blue"><font color="blue">common stock</font> could decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to Our Business       Our operating results are <font color="blue">substantially dependent upon</font> the <font color="blue">contribution</font> of     Sular, which has been below our <font color="blue"><font color="blue">acquisition</font> <font color="blue">expectations</font> since</font> we acquired     the product and which has <font color="blue"><font color="blue">adversely</font> affected</font> our operating results</td>
    </tr>
    <tr>
      <td>We acquired Sular in March 2002 and have not realized the <font color="blue">sales growth</font> for     Sular that we anticipated when we acquired it</td>
    </tr>
    <tr>
      <td>According to IMS Health’s National Prescription Audit Plus™ data,     total Sular <font color="blue"><font color="blue">prescription</font>s</font> increased 16dtta1prca for the year ended <font color="blue">December </font>31,     2005 compared to the year ended <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>Although we have revised     our operational plan to <font color="blue">focus on maximizing sales</font> of our <font color="blue"><font color="blue">existing product</font>s</font>,     <font color="blue">particularly</font> Sular, we may not be able to increase Sular <font color="blue"><font color="blue">prescription</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">potential growth rate</font> for Sular may be limited by the <font color="blue">contraction</font> of the     market for the class of drugs to which Sular belongs</td>
    </tr>
    <tr>
      <td>The <font color="blue">calcium channel blocker products market</font> is <font color="blue">contracting</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">contraction</font>     may be due to the following, all or any of which may have an adverse effect     on the sales of Sular:       ·       <font color="blue">published studies showing</font> that other classes of <font color="blue">drugs treating</font>     <font color="blue">hypertension</font> have <font color="blue">health benefits</font> in addition to <font color="blue"><font color="blue">controlling</font> blood pressure</font>;       ·       the <font color="blue">introduction</font> of new classes of <font color="blue">drugs treating</font> <font color="blue">hypertension</font>; and       ·       a reduction in the number of <font color="blue">companies actively promoting calcium</font>     channel blockers, which, in turn, has led to there being <font color="blue">less available</font>     information regarding <font color="blue">calcium channel blockers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font><font color="blue">could offer</font> a <font color="blue">product <font color="blue">competitive</font> with</font> Sular and our other     products</td>
    </tr>
    <tr>
      <td>A  <font color="blue">patent addressing</font> the <font color="blue">composition</font> of the active ingredient in <font color="blue">Sular     </font>expired in 1998 and a <font color="blue">patent covering</font> the <font color="blue"><font color="blue">manufacturing</font> process expired</font> in     2004</td>
    </tr>
    <tr>
      <td>Therefore, a <font color="blue">competitor</font> could introduce a <font color="blue">product <font color="blue">competitive</font> with</font>     Sular  containing  its  <font color="blue">same active</font> ingredient, although Sular remains     <font color="blue">protected under</font> a <font color="blue">patent addressing</font> its <font color="blue">coat core tablet</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such competing</font>     <font color="blue">product may reduce</font> our <font color="blue">potential sales</font> of Sular</td>
    </tr>
    <tr>
      <td>Further, if, and as the     patent  protection  for  our other products expires, <font color="blue">competitor</font>s could     introduce <font color="blue">competitive</font> <font color="blue">products which</font> may reduce our sales of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Sales  of  our  <font color="blue">Robinul  </font>products  have been <font color="blue"><font color="blue">adversely</font> affected</font> by the     <font color="blue">introduction</font> of <font color="blue">generic products</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, generics to our Robinul and Robinul Forte products were     <font color="blue">introduced into</font> the marketplace</td>
    </tr>
    <tr>
      <td>These products are expected to have an     adverse effect <font color="blue">on future revenues</font> of our Robinul products</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue"><font color="blue">successfully</font> integrate</font> Fortamet, Altoprev and <font color="blue">Triglide     </font>into our <font color="blue">existing <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>In March 2005, we acquired from Andrx Laboratories <font color="blue">certain rights</font> related to     the <font color="blue">drug products</font> Fortamet and Altoprev and engaged Andrx to <font color="blue">manufacture</font> and     <font color="blue">supply us with</font> Fortamet and Altoprev</td>
    </tr>
    <tr>
      <td>We also received FDA approval for     Triglide, a <font color="blue">fenofibrate</font> <font color="blue">formulation</font> for which we obtained exclusive rights     from <font color="blue">SkyePharma </font>in 2004</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue"><font color="blue">successfully</font> integrate</font> Fortamet,     <font color="blue">Altoprev  </font>and Triglide into our <font color="blue">existing <font color="blue">operations</font></font> and to achieve our     expected level of <font color="blue">return from</font> sales thereof depends on numerous factors</td>
    </tr>
    <tr>
      <td>The <font color="blue">integration</font> of these <font color="blue">products into</font> our <font color="blue">existing <font color="blue">operations</font></font> requires that     we make <font color="blue">adjustments</font> to our sales and <font color="blue">administrative functions</font></td>
    </tr>
    <tr>
      <td>For example,     we have hired and <font color="blue">may continue</font> to <font color="blue">hire <font color="blue">additional</font> sales <font color="blue">representatives</font></font> and     adjusted our <font color="blue">marketing strategy</font> to include these <font color="blue">newly launched products</font></td>
    </tr>
    <tr>
      <td>Furthermore, we have adjusted our <font color="blue">administrative processes</font> to <font color="blue">facilitate</font> the     sales of these products,       19     ______________________________________________________________________       including  hiring  <font color="blue">additional</font>  <font color="blue">administrative support <font color="blue">personnel at</font></font> our     <font color="blue">headquarters</font></td>
    </tr>
    <tr>
      <td>If  our  <font color="blue">integration</font>  of the <font color="blue">products into</font> our existing     <font color="blue">operations</font> is <font color="blue">unsuccessful</font> or delayed, then we may not achieve the expected     level of <font color="blue">return from</font> our sales of these products</td>
    </tr>
    <tr>
      <td>This could result in a     material adverse effect on our results from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further, to the     extent we <font color="blue">become unable</font> to timely <font color="blue">hire <font color="blue">additional</font> sales <font color="blue">representatives</font></font> to     sell these products, we may not achieve expected sales</td>
    </tr>
    <tr>
      <td>While we expect to extend our <font color="blue"><font color="blue">existing product</font> lines</font> and to increase our     sales of <font color="blue"><font color="blue">existing product</font>s</font> by offering a more complete line of treatment     <font color="blue">alternatives through</font> our <font color="blue">acquisition</font> of <font color="blue">certain rights</font> to the Fortamet,     <font color="blue">Altoprev  </font>and  Triglide products, there can be no assurance that these     expected synergies can be achieved</td>
    </tr>
    <tr>
      <td>In addition, if we experience <font color="blue"><font color="blue">difficult</font>y</font>     in <font color="blue">integrating</font> the <font color="blue">products into</font> our <font color="blue">existing <font color="blue">operations</font></font> or <font color="blue">marketing them</font>     through our <font color="blue">existing sales channels</font> or as part of our <font color="blue">existing product</font>     lines, we <font color="blue">may incur significant unplanned costs</font> to complete the <font color="blue">integration</font>     of the products</td>
    </tr>
    <tr>
      <td>If we do not realize the expected <font color="blue">synergies from</font> acquiring     the  products  or we <font color="blue">incur unexpected costs</font> to <font color="blue">integrate them into</font> our     <font color="blue">existing <font color="blue">operations</font></font>, then we may experience a material adverse effect to our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further, there can be no assurance that either Andrx or <font color="blue">SkyePharma </font>will     <font color="blue">supply us with</font> a <font color="blue">sufficient quantity</font> of products to meet our demand for     finished goods, products and samples or that the <font color="blue">products provided will meet</font>     our <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain a <font color="blue">sufficient quantity</font> or the     products  provided do not meet our <font color="blue">specifications</font>, then our ability to     fulfill orders for the <font color="blue">products could</font> be <font color="blue"><font color="blue">adversely</font> effected</font></td>
    </tr>
    <tr>
      <td>The 60 mg     Altoprev product has experienced <font color="blue"><font color="blue">manufacturing</font> issues</font></td>
    </tr>
    <tr>
      <td>If the issues recur     and cannot be resolved, our ability to acquire the product for sale and     sampling will be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In addition, the FDA is currently     <font color="blue">investigating</font>  Andrx,  the  <font color="blue">manufacture</font>r of Altoprev and Fortamet, for     potential good <font color="blue">manufacturing</font> practice violations</td>
    </tr>
    <tr>
      <td>Our ability to acquire and     sell  <font color="blue">Altoprev  </font>and  <font color="blue">Fortamet  </font>could  be  <font color="blue">adversely</font>  impacted  by this     <font color="blue">investigation</font></td>
    </tr>
    <tr>
      <td>At this time, we do not know when the FDA will conclude its     <font color="blue">investigation</font></td>
    </tr>
    <tr>
      <td>Our ability to engage a third party to <font color="blue">manufacture</font> and supply     us  with  Fortamet and Altoprev is restricted to a very limited set of     <font color="blue"><font color="blue">circumstances</font> under</font> our <font color="blue">current <font color="blue">agreement</font> with</font> Andrx, and we do not have the     right to engage a third party to <font color="blue">manufacture</font> Triglide under our <font color="blue">agreement</font>     with SkyePharma</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">provide customers with</font> the quantity of     <font color="blue">products ordered</font> or to <font color="blue">provide customers with</font> high quality <font color="blue">products on</font> a     <font color="blue">consistent</font>  basis,  then our <font color="blue"><font color="blue">relationship</font>s with</font> our <font color="blue">customers could</font> be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>This could result in a material adverse effect on our     results from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Pohl-Boskamp can terminate our rights to <font color="blue"><font color="blue">Nitrolingual </font>Pumpspray</font></td>
    </tr>
    <tr>
      <td><font color="blue">Nitrolingual </font> Pumpspray  is  one of our <font color="blue">key products</font></td>
    </tr>
    <tr>
      <td>Pohl-Boskamp can     terminate our <font color="blue">distribution</font> <font color="blue">agreement</font> for <font color="blue"><font color="blue">Nitrolingual </font>Pumpspray</font> if a company     with a <font color="blue">product <font color="blue">competitive</font> with</font> <font color="blue"><font color="blue">Nitrolingual </font>Pumpspray</font> acquires direct or     <font color="blue">indirect influence</font> or <font color="blue">control over us</font></td>
    </tr>
    <tr>
      <td>Pohl-Boskamp’s <font color="blue">termination</font> of our     <font color="blue">distribution</font> <font color="blue">agreement</font> could have a material <font color="blue">adverse impact on</font> our financial     results</td>
    </tr>
    <tr>
      <td>In the future, we may not be able to increase our sales of promoted products     <font color="blue">sufficiently</font> to compensate for the decrease in sales of our non-promoted     products</td>
    </tr>
    <tr>
      <td>We have <font color="blue">suffered <font color="blue">declining sales</font></font> of our non-promoted products, including our     Robinul and Tanafed lines, which accounted for 26prca of our <font color="blue">total sales</font>, or     dlra38dtta8 million, for the year ended <font color="blue">December </font>31, 2004 and 2prca of our total     sales, or dlra5dtta2 million, for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We plan to     compensate for this decline in <font color="blue">revenues by increasing sales</font> of our existing     <font color="blue">actively promoted products</font> and acquiring <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>However, we may not     be able to <font color="blue">increase sales</font> of <font color="blue">actively promoted products</font> or <font color="blue">locate attractive</font>     <font color="blue">acquisition</font> candidates and <font color="blue">successfully</font> complete an <font color="blue">acquisition</font> to offset     the <font color="blue">declining sales</font> of non-promoted products</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">introduce line</font> <font color="blue">extensions</font></font> of our <font color="blue"><font color="blue">existing product</font>s</font>, we     may not achieve our sales plan</td>
    </tr>
    <tr>
      <td>Part of our operating plan includes the <font color="blue">introduction</font> of line <font color="blue">extensions</font> of     our <font color="blue"><font color="blue">existing product</font>s</font> to create marketing <font color="blue">advantages</font> and extend the life     cycles of our products</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">introduce line</font>       20     ______________________________________________________________________       <font color="blue">extensions</font> for any reason, including our, or our <font color="blue">third party developers</font>’,     <font color="blue">inability</font> to obtain <font color="blue">necessary</font> FDA approval, we may not achieve our sales     plan and/or revenue growth</td>
    </tr>
    <tr>
      <td><font color="blue">Introductions </font>of line <font color="blue">extensions</font> of our <font color="blue"><font color="blue">existing product</font>s</font> may require that     we make unexpected changes in our estimates for future product returns and     reserves for <font color="blue">obsolete inventory</font> which would <font color="blue">adversely</font> affect our operating     results</td>
    </tr>
    <tr>
      <td>From time-to-time we may seek to <font color="blue"><font color="blue">introduce line</font> <font color="blue">extensions</font></font> on an unexpected     and <font color="blue">expedited basis</font> before we are able to reduce the levels of <font color="blue">inventories</font>     of <font color="blue">product which may</font> be rendered obsolete or otherwise <font color="blue"><font color="blue">adversely</font> affected</font> by     the <font color="blue">line extension</font></td>
    </tr>
    <tr>
      <td>This may require us to increase our estimate for returns     of product on hand at <font color="blue">wholesalers</font>, which is <font color="blue">recorded as</font> a reduction of our     net  revenues,  and increase our reserve for <font color="blue">obsolete inventory</font> in our     warehouse  which  is  <font color="blue">recorded as</font> a cost of revenues</td>
    </tr>
    <tr>
      <td>Accordingly, the     <font color="blue">introduction</font> of line <font color="blue">extensions</font> may <font color="blue">adversely</font> affect our operating results</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">grow will suffer</font> if we do not acquire or <font color="blue">license rights</font> to     <font color="blue">new products</font> and integrate them <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We depend on <font color="blue">acquisition</font>s of rights to <font color="blue">products from others as</font> our primary     source for <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Risks in acquiring and <font color="blue">integrating</font> <font color="blue">new products</font>     include the following:       ·       we may not be able to locate <font color="blue">new products</font> that we find attractive     and <font color="blue"><font color="blue">complement</font>ary</font> to our business;       ·       the price to acquire or obtain a license for these products may be     too costly to justify the <font color="blue">acquisition</font>;       ·       we may not be able to <font color="blue"><font color="blue">successfully</font> integrate</font> newly acquired products     into our <font color="blue">existing <font color="blue">operations</font></font> or the cost of <font color="blue">integration</font> may exceed our     <font color="blue">expectations</font>; and       ·       we may not realize our anticipated return on <font color="blue">investment</font> from our     sales of any <font color="blue">such newly</font> acquired products</td>
    </tr>
    <tr>
      <td>We <font color="blue">often face significant <font color="blue">competition</font> from</font> other <font color="blue"><font color="blue">pharmaceutical</font> companies</font> in     acquiring  rights  to  products, which makes it more <font color="blue">difficult</font> to find     <font color="blue">attractive <font color="blue">products on</font></font> acceptable terms</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">integration</font> of new     <font color="blue">products into</font> our <font color="blue">existing structure may</font> require unanticipated <font color="blue">investment</font>s     of time and resources or an expansion of our <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>If we are unable     to  acquire  or  <font color="blue">license rights</font> to <font color="blue">new products</font> or are <font color="blue">unsuccessful</font> in     <font color="blue">integrating</font> <font color="blue">such products</font>, our ability to <font color="blue">grow will suffer</font> and our operating     results may be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>As  part of our <font color="blue">growth strategy</font>, we may acquire <font color="blue">businesses</font>, which will     subject us to <font color="blue">additional</font> risks</td>
    </tr>
    <tr>
      <td>As  an  element of our <font color="blue">growth strategy</font>, we may acquire <font color="blue">businesses</font> with     products that <font color="blue">complement</font> our current products, and we have evaluated and     discussed  such  <font color="blue">opportunities</font> with interested parties in the past</td>
    </tr>
    <tr>
      <td>In     addition to the risks that we face in locating and <font color="blue">consummating new product</font>     <font color="blue">acquisition</font>s, we face the <font color="blue">following risks</font>, the occurrence of any or all of     which may <font color="blue">adversely</font> affect our business:       ·       we may realize substantial <font color="blue">acquisition</font>-related expenses, including     the <font color="blue">amortization</font> of long-lived assets, which would reduce our net income in     <font color="blue">future years</font>;       ·       our <font color="blue">investigation</font> of potential <font color="blue">acquisition</font> candidates may not reveal     problems and <font color="blue">liabilities</font> associated with the <font color="blue">businesses</font>, technologies or     products that we acquire;       ·       we may assume <font color="blue">liabilities</font> that increase our risks;       ·       we may not be able to <font color="blue">fully integrate</font> the acquired business or     <font color="blue">products into</font> our own; and       ·       we <font color="blue">may underestimate</font> the costs <font color="blue">necessary</font> to integrate and operate     the acquired business</td>
    </tr>
    <tr>
      <td>In addition, if we conduct <font color="blue">acquisition</font>s using convertible debt or equity     securities,  the  increased  number  of  shares may be dilutive to our     <font color="blue">shareholders</font>, and may result in <font color="blue">lower earnings per</font> share</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       We <font color="blue">may incur charges</font> for <font color="blue">intangible asset <font color="blue">impairment</font></font></td>
    </tr>
    <tr>
      <td>When we acquire the rights to <font color="blue">manufacture</font> and sell a product, we record the     aggregate  <font color="blue">purchase price</font>, along with the value of the product related     <font color="blue">liabilities</font>  we assume, <font color="blue">as <font color="blue">intangible assets</font></font></td>
    </tr>
    <tr>
      <td>We use the assistance of     <font color="blue">valuation experts</font> to <font color="blue">help us allocate</font> the <font color="blue">purchase price</font> to the <font color="blue">fair value</font>     of the <font color="blue">various <font color="blue">intangible assets</font></font> we have acquired</td>
    </tr>
    <tr>
      <td>Then, we must estimate     the <font color="blue">economic useful life</font> of each of these <font color="blue">intangible assets</font> in order to     amortize their cost as an expense in our statement of <font color="blue">operations</font> over the     estimated <font color="blue">economic useful life</font> of the related asset</td>
    </tr>
    <tr>
      <td>The factors that drive     the actual <font color="blue">economic useful life</font> of a <font color="blue"><font color="blue">pharmaceutical</font> product</font> are <font color="blue">inherently</font>     uncertain, and include patent protection, physician loyalty and prescribing     patterns, <font color="blue">competition</font> by products prescribed for similar <font color="blue">indications</font>, future     <font color="blue">introduction</font>s of <font color="blue">competing products</font> not yet FDA approved, the impact of     <font color="blue">promotional efforts</font> and many other issues</td>
    </tr>
    <tr>
      <td>We use all of these factors in     initially estimating the <font color="blue">economic useful lives</font> of our products, and we also     <font color="blue">continuously monitor</font> these factors for <font color="blue">indications</font> of <font color="blue"><font color="blue">appropriate</font> revisions</font></td>
    </tr>
    <tr>
      <td>In assessing the <font color="blue">recoverability</font> of our <font color="blue">intangible assets</font>, we must make     <font color="blue">assumptions</font> regarding estimated <font color="blue"><font color="blue">undiscounted</font> future <font color="blue">cash flow</font>s</font> and other     factors</td>
    </tr>
    <tr>
      <td>If the estimated <font color="blue"><font color="blue">undiscounted</font> future <font color="blue">cash flow</font>s</font> do not exceed the     carrying value of the <font color="blue">intangible assets</font> we must determine the <font color="blue">fair value</font> of     the <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">fair value</font> of the <font color="blue">intangible assets</font> is less     than its carrying value, an <font color="blue"><font color="blue">impairment</font> loss will</font> be recognized in an amount     equal to the difference</td>
    </tr>
    <tr>
      <td>If these estimates or their related <font color="blue">assumptions</font>     change in the future, we may be required to <font color="blue">record <font color="blue">impairment</font></font> changes for     these assets</td>
    </tr>
    <tr>
      <td>We review <font color="blue">intangible assets</font> for <font color="blue"><font color="blue">impairment</font> at least annually</font>     and <font color="blue">whenever events</font> or changes in <font color="blue"><font color="blue">circumstances</font> indicate</font> that the carrying     amount  of  an  asset  may not be recoverable</td>
    </tr>
    <tr>
      <td>As <font color="blue">circumstances</font> after an <font color="blue">acquisition</font> can change, the value of intangible     <font color="blue">assets may</font> not be realized by us</td>
    </tr>
    <tr>
      <td>If we determine that an <font color="blue">impairment</font> has     occurred, we would be required to write-off the impaired portion of the     unamortized <font color="blue">intangible assets</font>, <font color="blue">which could</font> have a material adverse effect on     our results of <font color="blue">operations</font> in the period in which the write-off occurs</td>
    </tr>
    <tr>
      <td>In     addition, in the event of a sale of any of our assets, we cannot be certain     that our <font color="blue">recorded value</font> of such <font color="blue">intangible assets</font> would be recovered</td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter problems</font> in the <font color="blue">manufacture</font> or supply of our products that     <font color="blue">could limit</font> our ability to sell our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend entirely on <font color="blue">third parties</font></font> to <font color="blue">manufacture</font> and supply our products</td>
    </tr>
    <tr>
      <td>Third parties <font color="blue">manufacture</font> and supply all of our products, and we do not     currently  have  <font color="blue">manufacturing</font>  <font color="blue">facilities</font>, personnel or access to raw     materials  to  <font color="blue">independently</font>  <font color="blue">manufacture</font> our products</td>
    </tr>
    <tr>
      <td>Except for any     <font color="blue">contractual rights</font> and <font color="blue">remedies which</font> we may have with our <font color="blue">manufacture</font>rs and     suppliers, we have <font color="blue">no control over</font> the <font color="blue">availability</font> of our products or their     quality or cost to us</td>
    </tr>
    <tr>
      <td>We do not maintain alternative <font color="blue">manufacturing</font> sources     for  any of our products, and we may not be able to <font color="blue">locate alternative</font>     <font color="blue">manufacture</font>rs  on  <font color="blue">commercially</font>  acceptable  terms  in  the event of a     <font color="blue">manufacturing</font> interruption or <font color="blue">termination</font> of an existing <font color="blue">manufacturing</font>     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In addition, third party <font color="blue">intellectual property</font> rights limit our ability to     <font color="blue">manufacture</font> and supply our products</td>
    </tr>
    <tr>
      <td>For example, due to the patent held on     <font color="blue">Nitrolingual </font> by our supplier, Pohl-Boskamp, <font color="blue">no alternative</font> source for     <font color="blue">Nitrolingual </font>exists</td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">third parties</font> hold the patents for the     <font color="blue">composition</font>  of  the <font color="blue">coat core tablet</font> for Sular, the <font color="blue">patent rights</font> for     Fortamet and Altoprev, the <font color="blue">patent rights</font> for Triglide, the <font color="blue">patent rights</font> for     the <font color="blue">manufacturing</font> process for raw materials in Tanafed DP and Tanafed DMX,     and the <font color="blue">patent rights</font> to Metafolin® , an active ingredient in Prenate Elite     and OptiNate</td>
    </tr>
    <tr>
      <td>In the event that these suppliers ceased to supply product to     us, we may not be able to locate another <font color="blue">manufacture</font>r or supplier who would     be able to <font color="blue">manufacture</font> or supply the products without violating such patents     or who could <font color="blue">manufacture</font> the <font color="blue">products on</font> <font color="blue">commercially</font> reasonable terms</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       We <font color="blue">may encounter <font color="blue">interruptions</font></font> in our supply of Cognex</td>
    </tr>
    <tr>
      <td>We are seeking a new     supplier to <font color="blue">supply us with</font> the active ingredient in Cognex</td>
    </tr>
    <tr>
      <td>Based on our     <font color="blue">current sales projections</font>, we believe that we have <font color="blue">adequate supplies</font> of the     active ingredient in Cognex for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>However, if sales     exceed our <font color="blue">current projections</font> or if we are unable to locate a <font color="blue">new supplier</font>     of the active ingredient in Cognex, our ability to sell Cognex would be     limited and our <font color="blue"><font color="blue">profitability</font> would</font> be reduced</td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue">manufacturing</font> <font color="blue">agreement</font>s for the majority of our products     require that we purchase our <font color="blue">product <font color="blue"><font color="blue">requirement</font>s</font> from</font> the <font color="blue">manufacture</font>rs     that are a party to those <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>This prevents our <font color="blue">entering into</font> more     advantageous <font color="blue">manufacturing</font> <font color="blue">agreement</font>s with other <font color="blue">manufacture</font>rs for these     products, except in very limited <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face generic</font> and other <font color="blue">strong <font color="blue">competition</font></font> that could lower prices and     unit  sales, and <font color="blue">competitor</font>s have recently introduced <font color="blue">new products</font> and     therapies that could make some of our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>In addition, some of our products are not     <font color="blue">protected by patents</font> and <font color="blue">face <font color="blue">competition</font> from less expensive products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>could develop <font color="blue">new products</font> to <font color="blue">compete with</font> these products or     could develop <font color="blue">generic versions</font> of <font color="blue">products with which</font> our <font color="blue">products compete</font></td>
    </tr>
    <tr>
      <td>Third-party payors can require <font color="blue">substitution</font> and <font color="blue">pharmacists</font> can substitute     generic or other <font color="blue">competitive</font> products for our <font color="blue">products even</font> if physicians     <font color="blue">prescribe them</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>agencies, third-party payors and <font color="blue">pharmacies often</font>     <font color="blue">put pressure on patients</font> to <font color="blue">purchase generic</font> or other products instead of     brand-name  products  as a way to <font color="blue">reduce healthcare costs</font></td>
    </tr>
    <tr>
      <td>Any further     increase in the amount of generic and other <font color="blue"><font color="blue">competition</font> against</font> any one or     more of our <font color="blue">products could</font> further lower prices and unit <font color="blue">sales <font color="blue">which could</font></font>     <font color="blue">adversely</font> affect our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">products compete</font> against products sold over-the-counter or     by  <font color="blue">prescription</font>  that  in  some  cases  are  marketed  by much larger     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> with greater financial resources for marketing and     <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>For example, Pfizer sells a <font color="blue">hypertension</font> product called     Norvasc which, as of <font color="blue">December </font>31, 2005 had a 45dtta5prca share of the calcium     channel blocker market (<font color="blue">based on</font> <font color="blue"><font color="blue">prescription</font>s</font> according to IMS Health’s     National Prescription Audit Plus™ data), and introduced a <font color="blue">combination</font> of     Norvasc  with its popular cholesterol-reducing product Lipitor, called     Caduet, <font color="blue"><font color="blue">which could</font> prove</font> to be an <font color="blue">attractive alternative</font> to our product     Sular</td>
    </tr>
    <tr>
      <td>Also, a <font color="blue">competitor</font> is developing a lingual <font color="blue">nitroglycerin</font> spray     similar to our <font color="blue">Nitrolingual </font>product, <font color="blue">which could</font> divert <font color="blue"><font color="blue">prescription</font>s</font> and     <font color="blue">reduce sales</font> of Nitrolingual</td>
    </tr>
    <tr>
      <td>Also, <font color="blue">based on</font> the <font color="blue">regulatory status</font> of our     Prenate Elite, OptiNate, Robinul, Tanafed, Zebutal, and Zoto-HC products,     barriers to entry for <font color="blue">products competing with</font> our products are low, which     makes  it  easier for <font color="blue">competitor</font>s to enter the market</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may     continue to develop <font color="blue">new products</font> and surgeons <font color="blue">may continue</font> to develop new     <font color="blue">surgical procedures</font> to <font color="blue">treat angina</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>are also developing new     products to treat short term pain and have recently developed new pain     therapies</td>
    </tr>
    <tr>
      <td>These <font color="blue">new products</font> and <font color="blue">procedures may reduce demand</font> for our     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">high level</font> of <font color="blue">competition</font> in our <font color="blue">industry could force us</font> to     reduce the <font color="blue">price at which</font> we sell our products or require us to spend more     to market our products, or both</td>
    </tr>
    <tr>
      <td>A small number of <font color="blue">customers account</font> for a large portion of our sales and the     loss of one of them, or changes in their purchasing patterns, could result     in <font color="blue">reduced sales</font> or <font color="blue">adversely</font> impact our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>For  the  year  ended <font color="blue">December </font>31, 2004, sales to <font color="blue"><font color="blue">McKesson Corporation </font>    </font>represented 31prca, <font color="blue">Cardinal Health Inc</font></td>
    </tr>
    <tr>
      <td>represented 25prca and AmerisourceBergen     Corporation  represented  22prca  of  our <font color="blue">total sales</font></td>
    </tr>
    <tr>
      <td>For the year ended     <font color="blue">December </font>31, 2005, sales to <font color="blue">McKesson Corporation </font>represented 30prca, Cardinal     Health Inc</td>
    </tr>
    <tr>
      <td>represented 23prca and <font color="blue">AmerisourceBergen Corporation </font>represented     10prca of our <font color="blue">total sales</font></td>
    </tr>
    <tr>
      <td>The small number of <font color="blue">wholesale drug <font color="blue">distributors</font></font>,     <font color="blue">consolidation</font>  in  this  industry  or  financial <font color="blue">difficult</font>ies of these     <font color="blue"><font color="blue">distributors</font> could</font> result in the <font color="blue">combination</font> or <font color="blue">elimination</font> of <font color="blue">warehouses</font>,     <font color="blue"><font color="blue">which could</font> temporarily increase returns</font> of our products or, as a result of     <font color="blue">distributors</font> reducing inventory levels, delay the purchase of our products</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       In  late 2002, our <font color="blue"><font color="blue">wholesaler customers</font> purchased excessive amounts</font> of     inventory of our products in <font color="blue">anticipation</font> of <font color="blue">future price increases</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">adversely</font> impacted our sales in the first half of 2003</td>
    </tr>
    <tr>
      <td>In response, in the     second and <font color="blue">third quarters</font> of 2003, we <font color="blue"><font color="blue">entered into</font> inventory <font color="blue">management</font></font>     <font color="blue">agreement</font>s with our three largest wholesale customers which offer <font color="blue">incentives</font>     to the wholesaler to maintain <font color="blue">level amounts</font> of inventory</td>
    </tr>
    <tr>
      <td>These <font color="blue">wholesalers</font>     may choose to forego the <font color="blue">incentives</font> and to maintain more <font color="blue">inventory than</font>     <font color="blue">contractually</font>  allowed</td>
    </tr>
    <tr>
      <td>While we have <font color="blue">instituted inventory <font color="blue">management</font></font>     <font color="blue">controls with</font> our <font color="blue">wholesaler customers</font>, the <font color="blue">controls rely upon data supplied</font>     by our <font color="blue">wholesaler customers</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that the <font color="blue">data supplied by</font>     our <font color="blue">wholesaler customers</font> will be accurate or that the <font color="blue">controls will</font> be     <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>If the wholesaler information is unreliable and our controls are     not <font color="blue">effective</font>, it could have a material adverse effect on our inventory     <font color="blue">management</font> and <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">products under <font color="blue">development</font></font> fail</font> in <font color="blue">clinical studies</font>, if we fail or     encounter <font color="blue">difficult</font>ies in obtaining <font color="blue">regulatory approval</font> for <font color="blue">new products</font> or     new  uses  of  <font color="blue"><font color="blue">existing product</font>s</font>, or if our <font color="blue">development</font> <font color="blue">agreement</font>s are     terminated, we will have <font color="blue">expended significant resources</font> for no return</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">third parties</font> to formulate, develop and <font color="blue">manufacture</font> the materials     needed for <font color="blue"><font color="blue">clinical trial</font>s</font> for our <font color="blue">products under <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>We also rely     on <font color="blue">third parties</font> to conduct <font color="blue"><font color="blue">clinical trial</font>s</font> for us</td>
    </tr>
    <tr>
      <td>If our products are not     successful in <font color="blue"><font color="blue">clinical trial</font>s</font> or we do not obtain FDA <font color="blue">marketing approval</font>, we     will have <font color="blue">expended significant resources</font> with no return</td>
    </tr>
    <tr>
      <td>For example, we have filed an IND with the FDA for <font color="blue">development</font> product     FHPC-02 and a Phase I <font color="blue">clinical trial</font> has been completed</td>
    </tr>
    <tr>
      <td>If we cannot obtain     FDA approval for this or other <font color="blue">products which</font> we may seek to develop in the     future, our <font color="blue">sales growth</font> may suffer</td>
    </tr>
    <tr>
      <td>We  may not receive FDA approvals for products and/or ongoing clinical     studies might be delayed or halted for <font color="blue">various reasons</font>, including:       ·       our products are not shown to be <font color="blue">effective</font>;       ·       we do not <font color="blue"><font color="blue">comply with</font> <font color="blue"><font color="blue">requirement</font>s</font> <font color="blue">concerning</font></font> the <font color="blue">investigation</font>al     <font color="blue">new drug application <font color="blue"><font color="blue">requirement</font>s</font></font> or protection of the rights and welfare of     <font color="blue">human subjects</font>;       ·       patients experience unacceptable side effects or die <font color="blue">during clinical</font>     trials;       ·       patients do not enroll in the <font color="blue">studies at</font> the rate we expect; and       ·        <font color="blue">product supplies</font> are delayed, are not sufficient to treat the     patients in the studies or are not <font color="blue">sufficiently</font> stable</td>
    </tr>
    <tr>
      <td>If third-party payors do not <font color="blue">adequately reimburse patients</font> for our products,     <font color="blue">doctors may</font> not <font color="blue">prescribe them</font></td>
    </tr>
    <tr>
      <td>Because our products are sold by <font color="blue">prescription</font>, we depend on third-party     payors, such as the government, private healthcare insurers and <font color="blue">managed care</font>     <font color="blue">organizations</font>, to include these <font color="blue">products on</font> their lists of products for     which  third-party  <font color="blue">payors will reimburse patients</font></td>
    </tr>
    <tr>
      <td>Third-party payors     regularly  challenge  the  pricing of <font color="blue">medical products</font> and <font color="blue">services by</font>     substituting cheaper <font color="blue">products on</font> their <font color="blue">approved lists</font></td>
    </tr>
    <tr>
      <td>Because our Zebutal,     Tanafed  line, Zoto, Robinul line, Ponstel and <font color="blue">Furadantin </font>products are     susceptible to generic <font color="blue">competition</font> and because of products that <font color="blue">compete with</font>     Sular, Prenate, <font color="blue"><font color="blue">Nitrolingual </font>Pumpspray</font>, Altoprev, Fortamet, Triglide and     Ponstel, we face an <font color="blue">increased risk</font> of third-party payors substituting these     products</td>
    </tr>
    <tr>
      <td>If third-party payors remove any of these products from their     lists or choose not to pay for our product <font color="blue"><font color="blue">prescription</font>s</font>, patients and     <font color="blue">pharmacies may</font> not continue to choose our products</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       We <font color="blue">rely on data</font> obtained from IMS <font color="blue">which could</font> be <font color="blue">inaccurate</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on operational data</font> obtained from IMS, an industry accepted data     source</td>
    </tr>
    <tr>
      <td>IMS data may not accurately reflect actual <font color="blue"><font color="blue">prescription</font>s</font> (for     instance, we believe IMS data does not capture all product <font color="blue"><font color="blue">prescription</font>s</font>     from some non-retail channels) or <font color="blue">trade levels</font> of inventory</td>
    </tr>
    <tr>
      <td>If IMS data     turns out to be <font color="blue">inaccurate</font> or unreliable and our controls are not <font color="blue">effective</font>,     <font color="blue">there could</font> be an adverse effect on our ability to <font color="blue">properly manage inventory</font>     and to our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>We depend on highly trained <font color="blue">management</font>, and we may not be able to keep     current <font color="blue">management</font> or hire qualified <font color="blue">management</font> personnel in the future</td>
    </tr>
    <tr>
      <td>We currently have a limited number of key executive, regulatory, technical     and <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>We may need to identify and <font color="blue">attract new executive</font>,     operational and <font color="blue">marketing personnel</font>, and we may have <font color="blue"><font color="blue">difficult</font>y</font> hiring     <font color="blue">personnel at</font> an acceptable cost</td>
    </tr>
    <tr>
      <td>While we <font color="blue">periodically address succession</font>     planning and the <font color="blue">possibility</font> of <font color="blue">key employees retiring</font>, our failure to     <font color="blue">successfully</font> identify and attract such personnel, as and when needed, could     limit our ability to continue our business at its current level and/or grow     our business</td>
    </tr>
    <tr>
      <td>The incurrence of <font color="blue">debt could reduce</font> our growth and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In March 2004, we issued a total of dlra150 million 1dtta75prca senior subordinated     <font color="blue"><font color="blue">contingent</font> convertible</font> notes due 2024 in <font color="blue"><font color="blue">transaction</font>s</font> that were <font color="blue">exempt from</font>     <font color="blue">registration under</font> the <font color="blue">Securities Act</font></td>
    </tr>
    <tr>
      <td>The notes are due March 8, 2024 and     accrued  interest  is  payable semi-annually in <font color="blue">arrears on</font> March 8 and     <font color="blue">September </font>8 of each year, commencing on <font color="blue">September </font>8, 2004</td>
    </tr>
    <tr>
      <td>In addition to     the <font color="blue">interest on</font> the notes, after March 8, 2007, we <font color="blue">will also pay <font color="blue">contingent</font></font>     <font color="blue">interest during specified six month periods</font> if the average <font color="blue">trading price</font> of     the notes per dlra1cmam000 principal amount for the <font color="blue">five day trading period</font> ending     on  the  third  <font color="blue">trading day immediately preceding</font> the first day of the     applicable six month period equals dlra1cmam200 or more</td>
    </tr>
    <tr>
      <td>During any period when     <font color="blue">contingent</font> interest is payable, it will be payable at a rate equal to 0dtta5prca     per annum</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2003, we <font color="blue">entered into</font> a credit <font color="blue">facility</font> for a dlra20dtta0 million     <font color="blue"><font color="blue">revolving loan</font> with various lenders</font> and <font color="blue">LaSalle Bank </font>National Association,     <font color="blue">as administrative agent</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may borrow under</font> the <font color="blue">revolving loan</font> and incur     other debt to finance <font color="blue">acquisition</font>s to implement our <font color="blue">growth strategy</font> and/or     for <font color="blue">general corporate purposes</font></td>
    </tr>
    <tr>
      <td><font color="blue">Borrowings </font>are <font color="blue">secured by substantially</font> all     of  the  Company’s assets</td>
    </tr>
    <tr>
      <td>We anticipate that we may amend this credit     <font color="blue">facility</font>  or  replace it with a new <font color="blue">facility</font> primarily to increase our     available  <font color="blue">borrowings</font>  so  as to <font color="blue">facilitate</font> future product <font color="blue">acquisition</font>     <font color="blue"><font color="blue">transaction</font>s</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had no outstanding <font color="blue">borrowings</font>     under our credit <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>debt could (1) limit our operating <font color="blue">flexibility as</font> a result of     <font color="blue"><font color="blue">requirement</font>s</font> by lenders, (2) require us to use a large portion of our cash     flow from <font color="blue">operations</font> for <font color="blue">debt service payments</font> that <font color="blue">could reduce profits</font> and     would reduce the <font color="blue">availability</font> of our <font color="blue">cash flow</font> to fund <font color="blue">operations</font>, product     <font color="blue">acquisition</font>s, the expansion of our <font color="blue">sales force</font> and <font color="blue">facilities</font> and research     and <font color="blue">development</font> efforts and (3) limit <font color="blue">acquisition</font>s of products or companies     due to <font color="blue">restrictive covenants under</font> our <font color="blue">senior secured</font> credit <font color="blue">facility</font> with     which we <font color="blue">must comply as long as</font> it is in effect</td>
    </tr>
    <tr>
      <td>We expect to need <font color="blue">additional</font> funds to acquire or obtain licenses for new     products, develop and test <font color="blue">new products</font> and <font color="blue">potentially</font> to acquire other     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>We may seek funding through public and <font color="blue">private financing</font> and may     seek to incur debt, <font color="blue">issue shares</font> of our stock, or both, either to finance a     <font color="blue">transaction</font> or <font color="blue">as consideration</font> for a <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>funds for these     purposes, whether through the <font color="blue">financial markets</font> or from other sources, may     not  be  available  when  we  need  them or on terms acceptable to us</td>
    </tr>
    <tr>
      <td><font color="blue">Insufficient </font><font color="blue">funds could</font> cause us to delay, scale back or abandon some or     all  of  our  product <font color="blue">acquisition</font>s, licensing <font color="blue">opportunities</font>, marketing     programs, product <font color="blue">development</font> programs, potential business <font color="blue">acquisition</font>s and     <font color="blue">manufacturing</font> <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       The <font color="blue">regulatory status</font> of some of our products makes these products subject     to increased <font color="blue">competition</font> and other risks</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory status</font> of some of our products may allow <font color="blue">third parties</font> to     more easily introduce <font color="blue">competitive</font> products, and may make it more <font color="blue">difficult</font>     for us to <font color="blue">sell certain</font> of our products in the future</td>
    </tr>
    <tr>
      <td>Currently, an FDA     <font color="blue">program allows us</font>, in our opinion, to <font color="blue">manufacture</font> and market certain of our     products, and <font color="blue">permits others</font> to <font color="blue">manufacture</font> and market similar products,     <font color="blue">without submitting safety</font> or <font color="blue">efficacy data</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>results in increased <font color="blue">competition</font> because other companies can enter the     <font color="blue">market without</font> having to <font color="blue">submit safety</font> and <font color="blue">efficacy data</font> to <font color="blue">sell competing</font>     products</td>
    </tr>
    <tr>
      <td>On  several  <font color="blue">occasions</font>, the FDA has considered changing the     classification of <font color="blue">certain single</font> entity and <font color="blue">combination</font> product types of     drugs from <font color="blue">prescription</font> to over-the-counter use, and <font color="blue">which permit sponsors</font>     to utilize foreign over-the-counter experience data to establish a product     as safe and <font color="blue">effective</font> for over-the-counter use in the <font color="blue">US If the FDA </font>does     change the classification, we might have to <font color="blue">reformulate certain</font> of our     products or <font color="blue">submit safety</font> and <font color="blue">efficacy data</font> on those products, <font color="blue">which could</font>     be costly, or we might have to <font color="blue">discontinue selling <font color="blue">certain products</font></font> if the     FDA does not approve our <font color="blue">marketing application</font></td>
    </tr>
    <tr>
      <td>We could lose third-party     <font color="blue">reimbursement</font> for these products and face increased <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>In addition, the FDA considers <font color="blue">certain products</font> to be new drugs, but has     indicated its intent to <font color="blue">exercise enforcement discretion</font> and not pursue     <font color="blue">regulatory action unless certain <font color="blue">conditions</font></font> occur</td>
    </tr>
    <tr>
      <td>If these <font color="blue">conditions</font> were     to  <font color="blue">materialize</font>,  or  the FDA <font color="blue">disagreed with</font> our <font color="blue">conclusions about</font> the     <font color="blue">regulatory status</font> of these products, we might be required to submit an NDA     and/or cease marketing until the FDA <font color="blue">grants approval</font> to do so</td>
    </tr>
    <tr>
      <td>The FDA could     also, at any time, <font color="blue">promulgate new <font color="blue">regulations</font></font> or policies to require the     submission of an NDA for each of these products</td>
    </tr>
    <tr>
      <td>Our business is <font color="blue">heavily regulated by governmental <font color="blue">authorities</font></font>, and failure     to  comply  with  <font color="blue">such regulation</font> or changes in <font color="blue">such regulation</font>s could     <font color="blue"><font color="blue">negatively</font> affect</font> our results</td>
    </tr>
    <tr>
      <td>Many <font color="blue">government <font color="blue">authorities</font> regulate</font> our business, including, <font color="blue">among others</font>,     the FDA, the SEC, foreign regulatory <font color="blue">authorities</font>, the Drug Enforcement     Administration, the Consumer Product Safety Commission, the Federal Trade     Commission, the Occupational Safety and Health Administration, the Centers     for Medicare and Medicaid Services, the Environmental Protection Agency, the     Department of Labor, state, local and <font color="blue">foreign governments</font> and the Internal     Revenue  Service</td>
    </tr>
    <tr>
      <td>We  may  incur  <font color="blue">significant expenses</font> to <font color="blue">comply with</font>     <font color="blue"><font color="blue">regulations</font> imposed by</font> these <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Also, our future results could be     <font color="blue">negatively</font>  impacted  by  changes  in <font color="blue">governmental regulation over</font> the     <font color="blue"><font color="blue">pharmaceutical</font> industry</font>, including regulation of Medicare, Medicaid and     similar programs, by reducing our revenue and profits and/or increasing our     costs and expenses in order to <font color="blue">comply with</font> <font color="blue">such regulation</font></td>
    </tr>
    <tr>
      <td>In addition, all     of  our third-party <font color="blue">manufacture</font>rs, third-party sample <font color="blue">distributors</font> and     <font color="blue"><font color="blue">product packaging</font> companies</font> are subject to <font color="blue">inspection by</font> the FDA and, in     <font color="blue">appropriate</font>  cases,  the  Drug  Enforcement Administration and foreign     <font color="blue">regulators</font></td>
    </tr>
    <tr>
      <td>Some of our third-party <font color="blue">manufacture</font>rs have received warning     letters  from  the  FDA  <font color="blue">concerning</font>  <font color="blue">noncompliance</font>  with <font color="blue">manufacturing</font>     <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>If  our  third-party <font color="blue">manufacture</font>rs and other supply and     <font color="blue">distribution</font>  <font color="blue">chain partners</font> do not <font color="blue">comply with</font> FDA <font color="blue">regulations</font> in the     future,  they may not deliver products to us or deliver samples to our     <font color="blue">representatives</font>, or we may have to <font color="blue">recall products</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">deficiencies</font>     observed  by  the  FDA  do not relate to our products, our third-party     <font color="blue">manufacture</font>rs,  third-party  sample <font color="blue">distributors</font> and <font color="blue">product packaging</font>     <font color="blue">companies may</font> be delayed in <font color="blue">manufacturing</font> and supplying our products to us     in a <font color="blue">timely manner until</font> they address their <font color="blue">compliance issues with</font> the FDA       Our warehouse <font color="blue">facility</font> is also subject to <font color="blue">inspection by</font> the FDA and the Drug     Enforcement  Administration</td>
    </tr>
    <tr>
      <td>If  we  do  not <font color="blue">comply with</font> FDA and Drug     Enforcement Administration <font color="blue">regulations</font>, we may not be able to <font color="blue">sell product</font>     to our customers</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       An adverse judgment in the securities class <font color="blue">action <font color="blue">litigation</font></font> in which we     and <font color="blue">certain <font color="blue">directors</font></font> and <font color="blue">executive officers</font> are <font color="blue"><font color="blue">defendants</font> could</font> have a     material adverse effect on our results of <font color="blue">operations</font> and liquidity</td>
    </tr>
    <tr>
      <td>We, <font color="blue">along with certain former</font> and <font color="blue">current officers</font> and <font color="blue">directors</font>, are named     <font color="blue">defendants</font> in a <font color="blue">consolidated securities lawsuit initiated on</font> August 22, 2002     in the United States <font color="blue">District Court </font>for the Northern District of Georgia</td>
    </tr>
    <tr>
      <td><font color="blue">Plaintiffs </font>in the class <font color="blue">action <font color="blue">litigation</font></font> alleged in <font color="blue">general terms</font> that we     violated Sections 11 and 12(a)(2) of the <font color="blue">Securities Act</font> of 1933, as amended,     (the “<font color="blue">Securities Act</font>”), and that we violated Sections 10(b) and 20(a) of the     <font color="blue">Securities <font color="blue">Exchange Act</font> </font>of 1934, as amended, (the “<font color="blue">Exchange Act</font>”), and     Rule 10b-5 promulgated thereunder</td>
    </tr>
    <tr>
      <td>In an amended complaint, plaintiffs     claimed  that  we  issued  a series of <font color="blue">materially</font> false and misleading     statements to the market in <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue">public offering on</font> April 24,     2002 and thereafter relating to alleged “channel stuffing” activities</td>
    </tr>
    <tr>
      <td>The     <font color="blue">amended complaint also</font> alleged <font color="blue">controlling</font> person <font color="blue"><font color="blue">liability</font> on behalf</font> of     certain  of  our  officers  under Section 15 of the <font color="blue">Securities Act</font> and     Section 20 of the <font color="blue">Exchange Act</font></td>
    </tr>
    <tr>
      <td><font color="blue">Plaintiffs </font>sought an <font color="blue">unspecified amount</font> of     <font color="blue">compensatory damages</font> in an amount to be <font color="blue">proven at trial</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">September </font>29, 2004, the <font color="blue">US <font color="blue">District Court </font>for the Northern District </font>of     Georgia dismissed, without prejudice, the class <font color="blue">action lawsuit</font></td>
    </tr>
    <tr>
      <td>Although the     class <font color="blue">action lawsuit</font> was dismissed, the court granted the plaintiffs the     <font color="blue">opportunity</font> to amend their complaint provided that the plaintiffs pay all of     the <font color="blue">defendants</font>’ fees and costs associated with filing the motions to dismiss     the  lawsuit</td>
    </tr>
    <tr>
      <td><font color="blue">Plaintiffs </font> did  not file a <font color="blue"><font color="blue">second amended complaint</font> as</font>     permitted,  but  instead  filed  a <font color="blue">motion asking</font> the <font color="blue">District Court </font>to     reconsider its <font color="blue">September </font>29, 2004 order and lift the condition that they     must pay <font color="blue">defendants</font>’ fees and costs before <font color="blue">further <font color="blue">amendment</font></font></td>
    </tr>
    <tr>
      <td>On June 22,     2005, the <font color="blue">District Court </font>denied plaintiffs’ motion and gave them another     <font color="blue">opportunity</font> to amend if they pay <font color="blue">defendants</font>’ fees and costs</td>
    </tr>
    <tr>
      <td><font color="blue">Plaintiffs </font>    chose not to file a <font color="blue">second amended complaint</font></td>
    </tr>
    <tr>
      <td>Instead, <font color="blue">plaintiffs filed</font> an     appeal to the United States Court of Appeals for the Eleventh Circuit</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">appeal currently</font> is pending</td>
    </tr>
    <tr>
      <td>Although the outcome of these <font color="blue">proceedings</font> is     not certain, an adverse judgment against us in this <font color="blue">litigation</font> could have a     material adverse effect on our results of <font color="blue">operations</font> and liquidity</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">risks associated with taxation</font> in <font color="blue">multiple <font color="blue">jurisdiction</font>s</font></td>
    </tr>
    <tr>
      <td>We are subject to taxation <font color="blue">in the US </font>and in <font color="blue">certain foreign <font color="blue">jurisdiction</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">effective</font> tax rate and <font color="blue">tax <font color="blue">liability</font></font> are determined by a number of     factors, including the amount of <font color="blue">taxable income</font> in <font color="blue">particular <font color="blue">jurisdiction</font>s</font>,     the tax rates in these <font color="blue">jurisdiction</font>s, tax treaties between <font color="blue">jurisdiction</font>s,     the extent to which we <font color="blue">transfer funds</font> to and <font color="blue">repatriate funds from</font> our     <font color="blue">subsidiaries</font> and future changes in laws</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse interpretation</font> or ruling     by one of the taxing <font color="blue">authorities</font> in a <font color="blue">jurisdiction</font> in which we operate or a     change in <font color="blue">law could increase</font> our <font color="blue">tax <font color="blue">liability</font></font> or result in the imposition     of penalty payments, <font color="blue">which could</font> <font color="blue">adversely</font> impact our operating results</td>
    </tr>
    <tr>
      <td>If we do not secure or <font color="blue">enforce patents</font> and other <font color="blue">intellectual property</font>     rights, we <font color="blue">could encounter increased</font> <font color="blue">competition</font> that would <font color="blue">adversely</font> affect     our operating results</td>
    </tr>
    <tr>
      <td>We  do  not  hold  patent  rights  covering all of the products we are     <font color="blue">distributing</font> and do not in some cases have the right to <font color="blue">enforce patents</font> our     <font color="blue">licensors</font>  hold</td>
    </tr>
    <tr>
      <td>Patent rights do not protect our Robinul, Ponstel and     <font color="blue">Furadantin </font>products from <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>We obtained exclusive <font color="blue">distribution</font>     rights  in  the  US  to distribute our Fortamet, Altoprev, Triglide,     Nitrolingual,  Tanafed DP and Tanafed DMX products but have no or only     limited  rights  to enforce the patents relating to these products</td>
    </tr>
    <tr>
      <td>We     obtained exclusive US <font color="blue">distribution</font> rights to Sular from Bayer</td>
    </tr>
    <tr>
      <td>Bayer holds     the  patent for the <font color="blue">composition</font> of the <font color="blue">coat core tablet</font> for Sular</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">exclusivity afforded by</font> any of these patents or rights could cease because     we have no rights or only limited rights to <font color="blue">enforce patents</font> or to require     <font color="blue">enforcement actions by</font> the owners of the patents</td>
    </tr>
    <tr>
      <td><font color="blue">Proceedings </font>involving our     rights in patents or <font color="blue">patent applications could</font> result in <font color="blue">adverse decisions</font></td>
    </tr>
    <tr>
      <td>In addition, the confidentiality <font color="blue">agreement</font>s required of our employees and     <font color="blue">third parties</font> may not <font color="blue">provide adequate protection</font> for our <font color="blue">trade secrets</font>,     know-how and other <font color="blue">proprietary</font> information which we rely on       27     ______________________________________________________________________       to develop and sell our products</td>
    </tr>
    <tr>
      <td>If any of our employees or <font color="blue">third parties</font>     disclose any of our <font color="blue">trade secrets</font> or know-how, we <font color="blue">could encounter increased</font>     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">products could</font> infringe the <font color="blue">intellectual property</font> rights of third     parties, <font color="blue">which could</font> require us to <font color="blue">pay license fees</font> or defend <font color="blue">litigation</font>     that would be expensive or <font color="blue">prevent us from selling products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font>, use or sale of our <font color="blue">products may infringe on</font> the patent,     trademark and other <font color="blue">intellectual property</font> rights of others</td>
    </tr>
    <tr>
      <td>Patent and     trademark infringement problems occur <font color="blue">frequently</font> in <font color="blue"><font color="blue">connection</font> with</font> the sale     and  marketing  of <font color="blue"><font color="blue">pharmaceutical</font> product</font>s</td>
    </tr>
    <tr>
      <td>If we do not avoid alleged     infringement of the <font color="blue">intellectual property</font> rights of others, we may need to     seek  a license to sell our products, defend an <font color="blue">infringement action</font> or     challenge the validity of the <font color="blue">intellectual property</font> in court, all of which     could be expensive and time consuming</td>
    </tr>
    <tr>
      <td>In addition, if we are <font color="blue">found liable</font>     for infringing a patent, we may have to <font color="blue">stop selling one</font> or more of our     products and pay damages</td>
    </tr>
    <tr>
      <td>It could be very costly if we have to defend the     patents or <font color="blue">trademarks covering</font> our products or if we were <font color="blue">found liable</font> for     infringement <font color="blue">which could</font> increase our costs and reduce our margins and net     income</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims and product recalls <font color="blue">could limit</font> sales and increase     costs</td>
    </tr>
    <tr>
      <td>Side <font color="blue">effects could</font> occur from the use of our products</td>
    </tr>
    <tr>
      <td>Side effects or     marketing or <font color="blue">manufacturing</font> problems pertaining to any of our <font color="blue">products could</font>     result  in material product <font color="blue">liability</font> claims or <font color="blue">adverse publicity</font></td>
    </tr>
    <tr>
      <td>These problems     often  occur  with  little or no notice in <font color="blue"><font color="blue">connection</font> with</font> the sale of     <font color="blue"><font color="blue">pharmaceutical</font> product</font>s</td>
    </tr>
    <tr>
      <td>We face an <font color="blue">exchange risk on foreign currency</font></td>
    </tr>
    <tr>
      <td>Our purchases of <font color="blue">Nitrolingual </font>from Pohl-Boskamp, our purchases of <font color="blue">Triglide     </font>from <font color="blue">Skyepharma </font>and our purchases of Sular from Bayer are made in Euros or     are otherwise impacted by <font color="blue">fluctuations</font> <font color="blue">in the US </font>dollar—Euro exchange rate</td>
    </tr>
    <tr>
      <td>Although we did not <font color="blue">enter into</font> any forward contracts in 2005, we may seek to     eliminate  risks  from foreign currency <font color="blue">fluctuations</font> after the time of     shipment of product by <font color="blue">entering into</font> forward contracts for these purchases     of <font color="blue">inventory at</font> the time of <font color="blue">product shipments</font></td>
    </tr>
    <tr>
      <td>The Company’s earnings and     <font color="blue">cash flow</font>s could be <font color="blue"><font color="blue">adversely</font> affected</font> in the future by the <font color="blue">relationship</font> of     the US <font color="blue">dollar with foreign currencies</font> and there can be no assurance that     any <font color="blue">hedging activity will</font> be successful in <font color="blue">protecting us from exchange risk</font></td>
    </tr>
    <tr>
      <td>We  face  market  risk  that we could be <font color="blue"><font color="blue">adversely</font> affected</font> by certain     <font color="blue">fluctuations</font> in <font color="blue">interest rates</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">fair value</font> of our <font color="blue">investment</font> portfolio would be <font color="blue"><font color="blue">negatively</font> affect</font>ed by     an  increase  in  interest  rates</td>
    </tr>
    <tr>
      <td>Since the majority of the Company’s     <font color="blue">investment</font>s are fixed rate interest-bearing securities and therefore subject     to the <font color="blue">market risk</font> of loss in <font color="blue">market value from</font> an increase in rates or a     change in the <font color="blue">underlying risk</font> of the issuers of the notes, the Company’s     <font color="blue">future earnings</font> and <font color="blue">cash flow</font>s could be affected <font color="blue">adversely</font> if the <font color="blue">Company     </font>were to sell the <font color="blue">securities prior</font> to their <font color="blue">maturity date</font></td>
    </tr>
    <tr>
      <td>We had realized     <font color="blue">losses from</font> the sale of <font color="blue">investment</font>s for the year ended <font color="blue">December </font>31, 2005 of     dlra0dtta7 million</td>
    </tr>
    <tr>
      <td>At <font color="blue">December </font>31, 2005, the Company had <font color="blue">total net unrealized</font>     <font color="blue">losses from</font> marketable securities of dlra2dtta0 million</td>
    </tr>
    <tr>
      <td>In  <font color="blue"><font color="blue">connection</font> with</font> <font color="blue">borrowings</font> incurred under the credit <font color="blue">facility</font> with     LaSalle Bank, we could experience <font color="blue">market risk</font> with respect to changes in the     <font color="blue">general level</font> of the <font color="blue">interest rates</font> and their effect upon our interest     expense</td>
    </tr>
    <tr>
      <td><font color="blue">Borrowings </font>under this <font color="blue">facility</font> bear interest at variable rates</td>
    </tr>
    <tr>
      <td>Because such rates are variable, an increase in <font color="blue">interest rates</font> will result     in <font color="blue">additional</font> interest expense and a reduction in <font color="blue">interest rates</font> will result     in <font color="blue">reduced interest expense</font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">present exposure</font> to interest     rate <font color="blue">fluctuations</font> is <font color="blue">primarily dependent on rate</font> changes that may occur     while <font color="blue">borrowings</font> under the <font color="blue">senior secured</font> credit <font color="blue">facility</font> are outstanding</td>
    </tr>
    <tr>
      <td>The Company’s long-term fixed <font color="blue">interest rate debt</font> is comprised of the Old     Notes, which are also subject to <font color="blue">market risk</font></td>
    </tr>
    <tr>
      <td>All other things being equal,     the fair market value of the Company’s fixed rate debt       28     ______________________________________________________________________       <font color="blue">will increase as rates decline</font> and <font color="blue">will decrease as rates rise</font></td>
    </tr>
    <tr>
      <td>The fixed     rate <font color="blue">Old Notes </font>outstanding, totaling dlra150dtta0 million at <font color="blue">December </font>31, 2005,     had a <font color="blue">fair value</font> of dlra138dtta1 million <font color="blue">based on</font> quoted market rates as of such     date</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our Common Stock       Our stock price has <font color="blue">been volatile</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">market price</font> for our securities has <font color="blue">been highly volatile</font></td>
    </tr>
    <tr>
      <td><font color="blue">Various     </font>factors,  including  factors  that  are  not  related to our operating     performance, may cause <font color="blue">significant volume</font> and price <font color="blue">fluctuations</font> in the     market</td>
    </tr>
    <tr>
      <td>The following factors, <font color="blue">among others</font>, may cause <font color="blue">fluctuations</font> in our     stock price:       ·        failure  to  meet  our financial estimates or <font color="blue">expectations</font> of     <font color="blue">securities analysts</font>;       ·       failure to increase <font color="blue"><font color="blue">prescription</font>s</font> of our products;       ·       the <font color="blue">introduction</font> of knock-offs or generics to our products;       ·       <font color="blue">fluctuations</font> in operating results;       ·       rates of <font color="blue">product acceptance</font>;       ·       timing or delay of <font color="blue">regulatory approval</font>s;       ·       <font color="blue">volatility</font> in the <font color="blue">pharmaceutical</font> and specialty <font color="blue">pharmaceutical</font> market     and stocks;       ·       if our third-party <font color="blue">manufacture</font>rs experience <font color="blue">interruptions</font> in the     supply  of  raw  materials,  encounter delays in shipping or encounter     <font color="blue">regulatory problems</font>;       ·       <font color="blue">development</font>s in or disputes regarding patent or other <font color="blue">proprietary</font>     rights; and       ·       general economic, market and political <font color="blue">conditions</font> not related to our     business</td>
    </tr>
    <tr>
      <td>Existing officers, <font color="blue">directors</font> and our <font color="blue">principal stockholder</font> own a substantial     block of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Existing officers, <font color="blue">directors</font> and our <font color="blue">principal stockholder</font> own a substantial     number of shares of our <font color="blue">common stock</font> that <font color="blue">may allow them</font> to elect <font color="blue">directors</font>     and direct the outcome of matters requiring <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, our officers, <font color="blue">directors</font> and our <font color="blue">principal stockholder</font>     <font color="blue"><font color="blue">beneficial</font>ly</font> owned <font color="blue">approximately</font> 22dtta4prca of our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As     of <font color="blue">December </font>31, 2005, Kapoor-Pharma Investments, LP <font color="blue"><font color="blue">beneficial</font>ly</font> owned     <font color="blue">approximately</font>  17dtta4prca  of  our  outstanding  <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Accordingly,     Kapoor-Pharma Investments holds <font color="blue">significant control</font> or <font color="blue">influence over</font> our     policies and acts</td>
    </tr>
    <tr>
      <td>John N Kapoor, Ph</td>
    </tr>
    <tr>
      <td>D, the Chairman of the Board of     Directors,   is   <font color="blue">President  </font>and  sole  stockholder  of  EJ  Financial     Enterprises, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">EJ Financial Enterprises </font>is the <font color="blue">managing general partner</font>     of Kapoor-Pharma Investments</td>
    </tr>
    <tr>
      <td>Kapoor is     trustee is a partner of Kapoor-Pharma Investments</td>
    </tr>
    <tr>
      <td>Anti-takeover  <font color="blue">provisions could discourage</font> a <font color="blue">third party from</font> making a     <font color="blue">takeover offer</font> that could be <font color="blue">beneficial</font> to <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Some of the provisions in our <font color="blue">restated certificate</font> of <font color="blue">incorporation</font> and     bylaws,  our <font color="blue">shareholder protection rights</font> plan, and the anti-takeover     <font color="blue">provisions under</font> <font color="blue">Delaware </font><font color="blue">law could delay</font> or prevent a <font color="blue">third party from</font>     acquiring us or <font color="blue">replacing members</font> of our Board of Directors, even if the     <font color="blue">acquisition</font> or the <font color="blue">replacements would</font> be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These provisions could also reduce the price that <font color="blue">certain investors might</font> be     willing to pay for shares of our <font color="blue">common stock</font> and/or New Notes and result in     the <font color="blue">market price</font> being lower than it would be without these provisions</td>
    </tr>
    <tr>
      <td>Our     charter and other documents contain anti-takeover devices including:       ·       <font color="blue">staggered director terms such</font> that only one of the <font color="blue">three classes</font> of     <font color="blue">directors</font> is <font color="blue">elected each year</font>;       ·        a <font color="blue">shareholder rights</font> plan that is designed to <font color="blue">protect us from</font>     <font color="blue">coercive takeover attempts</font>;       29     ______________________________________________________________________       ·       a <font color="blue">supermajority provision</font> requiring at least two-thirds of the     <font color="blue">shares entitled</font> to vote to approve an <font color="blue">amendment</font> of our bylaws;       ·       providing our <font color="blue">Board of Directors </font>with the authority to <font color="blue">issue shares</font>     of “blank-check” preferred stock without <font color="blue">stockholder approval</font> under any     terms, <font color="blue">conditions</font>, rights and <font color="blue">preferences</font> that the Board determines; and       ·        an advance notice <font color="blue">requirement</font> for <font color="blue">nominations</font> of <font color="blue">directors</font> or     proposals for <font color="blue">consideration at stockholder meetings</font></td>
    </tr>
  </tbody>
</table>